Senior Director, Global Commercial Development, Early Detection & Market Shaping

Revolution Medicines

3d•$232,000 - $290,000•Remote

About The Position

Revolution Medicines is seeking a Senior Director to lead global commercial strategy for enabling earlier identification and diagnosis of pancreatic cancer. Reporting to the Executive Director, Early Stage, Global Commercial Development – Pancreatic Cancer, this strategic and hands-on role will shape the early-detection ecosystem by connecting science, screening and surveillance pathways, diagnostic innovation, healthcare delivery, and disease education with the company’s longer-term early-stage portfolio ambitions. The role requires deep cross-functional influence, external ecosystem engagement, and the ability to build markets before established commercial pathways exist. The position is primarily remote, with travel for scientific, stakeholder, and team meetings; up to 50% travel is required. The role will lead global market-shaping strategy, patient-journey analysis, diagnostics assessment, ecosystem development, market insights and forecasts, education strategies, evidence and access planning, stakeholder engagement, portfolio coordination, strategic planning, partner management, and modern commercial capabilities. The posted base pay salary range is $232,000–$290,000 USD for candidates working onsite at the Redwood City, California headquarters, adjusted for local market.

Requirements

Bachelor’s degree with at least 15 years, or an advanced degree with at least 8 years, of progressive commercial experience in a biotechnology and/or pharmaceutical company, including strategic marketing and ideally sales.
Proven success developing and executing global commercial strategy and influencing cross-functional product or disease-area teams.
Demonstrated ability to derive actionable insights and analytics that inform innovative commercial strategies and investment decisions.
Strong leadership, including the ability to lead teams, collaborate effectively across functions, and influence without direct authority.
Excellent organizational skills and ability to prioritize effectively and deliver results within established timelines.
Strong clinical and scientific acumen, including the ability to translate preclinical and clinical data into commercial implications.
Excellent written, verbal, and executive communication skills, with the ability to represent Revolution Medicines effectively with external stakeholders.
Entrepreneurial mindset, comfort with ambiguity, and passion for improving outcomes for people with cancer.
Ability to assess the clinical, economic, and practical feasibility of screening, surveillance, and diagnostic strategies while scientific and commercial evidence continues to evolve.

Nice To Haves

Experience in pancreatic or other gastrointestinal cancers, oncology diagnostics, or development of new disease-area markets.
Experience with screening or surveillance initiatives, molecular diagnostics, liquid biopsy, imaging, or AI-enabled diagnostic pathways.
Experience building external alliances across industry, academic medicine, patient advocacy, and healthcare systems.
Prior involvement with a global oncology product launch or major market-creation initiative in a competitive environment.
Experience in a smaller, rapidly growing company with evolving operating models.

Responsibilities

Own the global commercial market-shaping strategy for pancreatic cancer early detection, including high-risk identification, surveillance, symptom recognition, diagnostic work-up, and referral to multidisciplinary care.
Map barriers and opportunities across the patient journey from first symptoms or high-risk status through imaging, testing, specialist referral, diagnosis, staging, and treatment access; develop hypotheses to improve pathways to earlier-stage care.
Assess emerging blood-based detection tests, molecular biomarkers, AI-enabled imaging, radiology tools, and other diagnostic approaches, translating evidence maturity and workflow requirements into commercial implications.
Develop a strategic map of academic centers, NCI and other research networks, healthcare delivery partners, technology and diagnostic companies, and patient advocacy organizations; recommend priority partnership opportunities.
Lead global market research, epidemiology and patient-flow analyses, screening and adoption scenarios, potential stage-shift assumptions, and evidence-based assessments of the opportunity and investment required for earlier diagnosis.
Partner with Medical Affairs, Corporate Affairs, Patient Advocacy, and appropriate review functions on compliant, unbranded disease-awareness, provider-education, and patient-engagement strategies addressing knowledge and referral gaps.
Collaborate with Clinical Development, Medical Affairs, Precision Medicine/Diagnostics, Market Access, and external partners to identify evidence needs, operational dependencies, and payer or health-system considerations for emerging detection approaches.
Translate insights from gastroenterologists, high-risk surveillance programs, primary care, radiology, genetics, pancreatic surgeons, oncology teams, and advocacy groups into practical market-shaping priorities.
Coordinate with daraxonrasib and zoldonrasib early-stage commercial leaders so early-detection planning reflects likely treatment pathways, molecular testing needs, and future patient-identification opportunities.
Prepare executive-level recommendations, scenario analyses, measurable milestones, and phased investment plans; align U.S. and key ex-U.S. perspectives with the broader pancreatic cancer disease-area strategy.
Select and direct agencies, research vendors, and specialist partners; establish effective ways of working and deliver integrated, high-quality outputs within budget.
Partner with IS Commercial and analytics teams to apply digital, omnichannel, and data-driven approaches to ecosystem intelligence and appropriately reviewed disease education.